Who is sponsoring NCT06015061?

NCT06015061 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT06015061?

Interventions in NCT06015061: Contrast-enhanced ultrasound(CEUS).

What condition does NCT06015061 study?

NCT06015061 studies Pheochromocytoma, Metastatic, Ultrasonography, Paraganglioma, Malignant, Pheochromocytoma Malignant.

Is NCT06015061 still recruiting?

NCT06015061 is currently status unknown. Last updated 29 August 2023.

Last reviewed 2023-08-29 · How we verify

NCT06015061

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prediction and Evaluation of Anlotinib Treatment Response Using Contrast Enhanced Ultrasound PPGL Patients

Status unknown Last updated 29 August 2023

What this trial tests

trial testing Contrast-enhanced ultrasound(CEUS) in Pheochromocytoma, Metastatic in 20 participants. Status unknown.

Timeline

1 March 2023

Primary endpoint
1 March 2025

1 March 2025

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	20
Start date	1 March 2023
Primary completion	1 March 2025
Estimated completion	1 March 2025
Sites	1 location across China

Drugs / interventions tested

Contrast-enhanced ultrasound(CEUS)

Conditions studied

Pheochromocytoma, Metastatic — all drugs for Pheochromocytoma, Metastatic →
Ultrasonography — all drugs for Ultrasonography →
Paraganglioma, Malignant — all drugs for Paraganglioma, Malignant →
Pheochromocytoma Malignant — all drugs for Pheochromocytoma Malignant →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 80, any sex, with Pheochromocytoma, Metastatic or Ultrasonography. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Anlotinib is a multi-target receptor tyrosine kinase inhibitor (TKI) targeting tumor angiogenesis and growth. The purpose of this study is to evaluate the efficiency of contrast enhanced ultrasound in assessing effectiveness of anlotinib in patients with locally advanced, metastatic, or unresectable pheochromocytoma or paraganglioma(PPGL).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06015061 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 29 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06015061.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing